Schedule 13G ownership disclosure
X4 PHARMACEUTICALS INC
Common Stock · CUSIP: 98420X103
Event date: 2024-12-31
- Filing-level shares
- 8,200,903
- Percent of class
- 4.8%
- The Vanguard Group
Shares: 8,200,903 · Class: 4.8%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0000932471-25-000265
- Form type
- SCHEDULE 13G/A
- Filer
- VANGUARD GROUP INC
- CIK
- CIK 102909
- Filed
- Jan 31, 2025
- Reporting period
- Dec 31, 2024
- Description
- Schedule 13G beneficial ownership